SLE - SYSTEMIC LUPUS ERYTHEMATOSUS
Clinical trials for SLE - SYSTEMIC LUPUS ERYTHEMATOSUS explained in plain language.
Never miss a new study
Get alerted when new SLE - SYSTEMIC LUPUS ERYTHEMATOSUS trials appear
Sign up with your email to follow new studies for SLE - SYSTEMIC LUPUS ERYTHEMATOSUS, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
By submitting, you agree to our Terms of use
-
Lupus drug belimumab under the microscope: can it prevent organ damage?
Disease control Recruiting nowThis study looks at whether the drug belimumab can prevent serious lupus flares that affect major organs. Researchers will compare lupus patients taking belimumab with those on standard treatments, using medical records and new data from about 684 adults in Greece. The goal is to…
Matched conditions: SLE - SYSTEMIC LUPUS ERYTHEMATOSUS
Sponsor: Biomedical Research Foundation, Academy of Athens • Aim: Disease control
Last updated Jun 16, 2026 12:53 UTC
-
New drug CC312 tested for tough autoimmune cases
Disease control Recruiting nowThis early study tests the safety of a new drug, CC312, in 6 adults with lupus, myositis, or scleroderma that has come back or not responded to standard treatments. The main goal is to check for side effects, not to cure the disease. Participants will receive multiple doses of th…
Matched conditions: SLE - SYSTEMIC LUPUS ERYTHEMATOSUS
Phase: EARLY_PHASE1 • Sponsor: CytoCares Inc • Aim: Disease control
Last updated Jun 16, 2026 12:52 UTC
-
Cord blood cells take on lupus: a new hope for patients who failed standard treatments
Disease control Recruiting nowThis early-phase study tests a new treatment for adults with severe lupus that hasn't responded to standard therapies. The treatment uses specially engineered immune cells from donated umbilical cord blood to target and calm the overactive immune system. The main goals are to che…
Matched conditions: SLE - SYSTEMIC LUPUS ERYTHEMATOSUS
Phase: EARLY_PHASE1 • Sponsor: Chengdu Ucello Biotechnology Co., Ltd. • Aim: Disease control
Last updated Jun 15, 2026 19:07 UTC
-
New lupus drug candidate enters first human safety trial
Disease control Recruiting nowThis early-stage study tests a new drug called CC312 in 32 adults with moderate-to-severe lupus. The main goal is to check safety and how the body handles the drug, not to cure the disease. Participants will receive either CC312 or a placebo, and researchers will monitor side eff…
Matched conditions: SLE - SYSTEMIC LUPUS ERYTHEMATOSUS
Phase: PHASE1 • Sponsor: CytoCares Inc • Aim: Disease control
Last updated Jun 12, 2026 12:07 UTC
-
Engineered immune cells take on lupus and scleroderma in early trial
Disease control Recruiting nowThis early-stage study tests a new treatment called QT-019C for people with severe autoimmune diseases like lupus and scleroderma that haven't responded to standard therapies. The treatment uses specially engineered immune cells (CAR T-cells) to target and destroy faulty immune c…
Matched conditions: SLE - SYSTEMIC LUPUS ERYTHEMATOSUS
Phase: PHASE1 • Sponsor: Institute of Hematology & Blood Diseases Hospital, China • Aim: Disease control
Last updated Jun 08, 2026 13:06 UTC
-
Experimental cell therapy offers hope for tough lupus cases
Disease control Recruiting nowThis study tests a new treatment called MB-CART19.1 for people with severe systemic lupus erythematosus (SLE) that hasn't improved with standard therapies. About 29 adults will receive this cell therapy to see if it can reduce disease activity and help achieve remission. The goal…
Matched conditions: SLE - SYSTEMIC LUPUS ERYTHEMATOSUS
Phase: PHASE1, PHASE2 • Sponsor: Miltenyi Biomedicine GmbH • Aim: Disease control
Last updated Jun 05, 2026 12:08 UTC